Prostin VR Pediatric Articles
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
MUSE In Sweden
4 November 1996
Vivus get Approvable Letter For MUSE
14 October 1996
Pressure On Japan's Drugmakers To Rationalize
19 August 1996
Astra Gets Rights To alprostadil
10 June 1996
Pfizer's Impotence Pill Shows Promise
13 May 1996
Harvard's Impotence Product
6 May 1996
VIVUS Filed NDA For Impotence Product
8 April 1996
Schwarz Pharma To Buy German Generics Firm
4 December 1995
Mixed Interims From Japanese Drug Majors
20 November 1995
Schwarz Pharma's Vasoprost: FDA says no...
30 October 1995
....And Ono Pharma Makes Fiscal 1996 Forecast
16 October 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
Marriage Of Pharmacia And Upjohn Will Create New $13 Bill Drug Group
4 September 1995
Correction: Upjohn's Minoxidil In Impotence
14 August 1995
Upjohn's Caverject Approved In The USA
17 July 1995
Two More Launches For Upjohn's Freedox
24 April 1995
Green Cross' Sales Advance in 1994
3 April 1995
New Japanese NDAs Filed
5 September 1994
CAVERJECT INTRODUCTION IN UK
18 April 1994
UPJOHN OUTLINES STRATEGIC DIRECTIONS
18 April 1994
FIRST APPROVAL FOR UPJOHN'S CAVERJECT
21 February 1994
UPJOHN ANTI-HIV AGENTS IN PHASE II TRIALS
5 April 1993
Taisho experiences profitable year
22 June 1992
ITALY'S RECORDATI LOOKS FOR EXPANSION
15 June 1992
ONO HAS GOOD YEAR AND CONSOLIDATES
15 June 1992
UPJOHN UPDATES ON R&D PROGRESS
13 April 1992
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
